MARKET

OXFD

OXFD

Oxford Immunotec
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.31
+0.83
+5.73%
After Hours: 15.31 0 0.00% 16:00 12/04 EST
OPEN
14.48
PREV CLOSE
14.48
HIGH
15.36
LOW
14.24
VOLUME
155.40K
TURNOVER
--
52 WEEK HIGH
17.77
52 WEEK LOW
8.37
MARKET CAP
397.48M
P/E (TTM)
-23.9443
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Oxford Immunotec Global inks distribution pact with RIKEN Genesis
Oxford Immunotec Global (OXFD) and RIKEN Genesis Co, a subsidiary of The Sysmex Corporation (Sysmex), in Japan come together, where latter will exclusively distribute the T-SPOT Discovery SARS-CoV-2 kit, developed by Oxford Immunotec
Seekingalpha · 2d ago
Oxford Immunotec Signs Exclusive Distributor Agreement With RIKEN Genesis To Market T-SPOT Discovery SARS-CoV-2 Kit For The Measurement Of The T cell Immune Response To SARS-CoV-2 Infection In Japan
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (NASDAQ:OXFD) (the "Company"), a global, high-growth diagnostics company today announces it has
Benzinga · 2d ago
Oxford Immunotec Signs Exclusive Distributor Agreement with RIKEN Genesis, a Subsidiary of Sysmex, to Market the T-SPOT® Discovery SARS-CoV-2 Kit for the Measurement of the T cell Immune Response to SARS-CoV-2 Infection in Japan
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has entered into an exclusive distribution agreement with RIKEN Genesis Co., Ltd, a subsidiary of The Sysmex Corporation (Sysmex), in Japan. Under the agreement, RIKEN Genesis will exclusively distribute the T-SPOT Discovery SARS-CoV-2 kit (Research Use Only), developed by Oxford Immunotec for the detection and measurement of SARS-CoV-2 specific T cells, which may offer new insight into immunity to SARS-CoV-2 infection.Based on the company’s T-SPOT technology, the only globally approved ELISPOT currently used clinically for the diagnosis of Tuberculosis infection; the T-SPOT Discovery SARS-CoV-2 kit is already available for research use across Europe and the USA. Trial data recently released by Public Health England1 using the T-SPOT Discovery SARS-CoV-2 kit suggests that individuals with SARS-CoV-2 specific T cells but without detectible antibodies (serology) may be protected from infection.Sysmex are committed to the establishment of diagnosis/treatment methods for COVID-19 and already offer PCR tests, antigen tests, and antibody tests. Following a successful trial of the T-SPOT Discovery SARS-CoV-2 kit in Japan, Sysmex believe offering a T cell response kit will form an important adjunct to their current range of tests for COVID-19.Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec, said “We’ve been working with RIKEN Genesis for almost ten years now in Japan and we are delighted to deepen our partnership with this distribution arrangement for our research use SARS-CoV-2 T cell test. RIKEN’s strong channel to research customers in Japan will help broaden usage of our T-SPOT Discovery SARS-CoV-2 kit, which we believe will be able to make a significant contribution in informing how we can better manage the ongoing pandemic.”Dr. Naoto Kondo, President and CEO of RIKEN Genesis, said “We are excited to start handling T-SPOT Discovery SARS-CoV-2 kit in Japan. We have provided the T-SPOT technology to Japan market in strong collaboration with Oxford Immunotec. We hope this kit will contribute to research support and drug development for COVID19, especially vaccine development.”T-SPOT Discovery SARS-CoV-2 is for research use only, not for use in diagnostic procedures.Not all products are available in all regions; please contact us for information on availability in any specific country.For further information on T-SPOT Discovery SARS-CoV-2 visit: https://www.tspotdiscovery.com.About Oxford ImmunotecOxford Immunotec Global PLC is a global, high-growth diagnostics company. We bring energy and invention to a world in need of diagnostic truth. We are uniquely placed as the only company in the world offering regulated ELISPOT assays for T cell measurement, with approval around the globe. Our leading product, the T-SPOT®.TB test, is used for diagnosing infection with Tuberculosis, the world’s largest cause of death from infectious disease. The Company is an experienced manufacturer of IVD tests, operating under a fully audited Quality Management System, ensuring rigorous batch control. The company has manufactured in excess of 20 million clinical T cell tests for TB infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.About RIKEN GenesisEstablished in October 2007, RIKEN Genesis (a subsidiary of The Sysmex Corporation) provides products for genetic testing based on cutting-edge gene analysis technology and laboratory assay services with the mission of realizing precision medicine using genomic science and molecular diagnostic technology joined the Sysmex Group in June 2016 for the practical application of genomic medicine. RIKEN Genesis provides highly reliable tests based on international quality standards in laboratories that have obtained CAP certification / CLIA certification and ISO 15189 certification, and has a track record in clinical sequence, drug discovery research support, and clinical research support. Additional information can be found at the RIKEN Genesis website www.rikengenesis.jp or at The Sysmex Corporation site https://www.sysmex.co.jp/en/.About T-SPOT Discovery SARS-CoV-2Oxford Immunotec has been developing and strengthening its expertise in T cell measurement for over 15 years since the introduction of its T-SPOT technology in the field of TB diagnostics. In that time, we have taken the classic ELISPOT technique and developed it into the world leading proprietary T-SPOT technology platform we now use to measure T cell immune responses, improving performance, standardising results, and streamlining the workflow. This high performance is ensured by our regularly audited manufacturing facility operating to our rigorous quality management system. The T-SPOT.TB test, an in vitro diagnostic (IVD) test using the T-SPOT technology platform, has been granted regulatory approval for clinical diagnostic use in over 50 countries, including US, EU, Japan and China. The research use-only T-SPOT Discovery SARS-CoV-2 assay uses this same T-SPOT technology to allow SARS-CoV-2-specific T cells to be detected and enumerated. The optimized antigen mix used in the test is based on SARS-CoV-2 structural proteins and allows the maximum breadth of the immune response to be measured. The Companies single antigen-per-well approach allows specific information about the immune response to different SARS-CoV-2 antigens to be gathered in parallel. Sample processing can be centralised whilst still enabling testing on fresh (rather than frozen) blood, using the Company’s T-Cell Xtend® reagent (32 h room temperature (RT) sample stability) or T-Cell Select™ reagent (54 h RT sample stability - automated processing). The T-Cell Select reagent kit also allows for automation and therefore accommodates variations in scale - automation solutions are available for low, medium and high throughput settings.T-SPOT, the Oxford Immunotec logo, T-Cell Xtend, T-Cell Select and T-SPOT Discovery are trademarks of Oxford Immunotec Limited.Forward-Looking StatementsCertain statements in this press release constitute forward-looking statements within the meaning of applicable U.S. and U.K. laws and regulations, including under the U.S. Private Securities Litigation Reform Act of 1995. Any statements contained herein which do not describe historical or current facts, including beliefs the Company’s distribution arrangement with RIKEN Genesis to market the T-SPOT® Discovery SARS-CoV-2 kit for the measurement of the T cell immune response to SARS-CoV-2 infection in Japan will provide data that provides new insights into immunity to COVID-19, including the belief that measuring T cells, in conjunction with other tests, may overcome limitations with the measurement of antibody-mediated immunity as well as other expected benefits of the T-SPOT Discovery SARS-CoV-2 test kit, including that the T cell assay may support efforts to combat COVID-19 and beliefs that the distribution arrangement will yield important information constitute forward-looking statements. Any forward-looking statements are based on our management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the possibility that the distribution arrangement will not yield the expected benefits in a timely manner or at all, or that the results of the initial data analyses will not contribute to the study or assisting in COVID-19 efforts as expected; the Company’s Discovery line of testing might not be a successful or timely tool in combatting COVID-19, the risk that further research data from the Discovery test kit will not produce results that support its clinical use, the likelihood that the Company will be able to partner with a third party to make a testing device clinically available and the possibility that, even if ultimately made commercially available, the testing kit will not be efficacious in testing for or combatting COVID-19, as well as those other risks and uncertainties described in Oxford Immunotec’s filings with the U.S. Securities and Exchange Commission (the “Commission”), including the Company’s Annual Report on Form 10-K for the year-ended December 31, 2019 and its Quarterly Report on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020 and in any other reports it files with the Commission, including any other Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Oxford Immunotec’s filings with the Commission are available for free by visiting the investor section of our website, www.oxfordimmunotec.com, or the Commission’s website, www.sec.gov.Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. Investors should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. Oxford Immunotec does not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.For Investor Inquiries: Matt McLaughlin Chief Financial Officer Oxford Immunotec Tel: +1 (508) 573-9953 mtmclaughlin@oxfordimmunotec.com1 To view the PHE publication visit: https://www.medrxiv.org/content/10.1101/2020.11.02.20222778v1
GlobeNewswire · 2d ago
Oxford Immunotec to Hold a Virtual Investor Event on December 17, 2020
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to hold a virtual investor event on Thursday, December 17, 2020. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will host a conference call from 10:00 a.m. to 12:00 p.m. Eastern Time. The call will be concurrently webcast with a slide presentation. The call topics will include: * A deep dive into the TB market and how investments made over the past few years have re-positioned the Company to capitalise on what the Company believes is a great long-term growth opportunity. This will include an update on the Company’s automation plans and the role the Company believes automation will play in driving that growth. * The longer term vision for the Company including the role of both organic and inorganic initiatives and deployment plans for the Company’s balance sheet. * A briefing on the Company’s SARS-CoV-2 plans. The Company will provide its views, based on the significant base of evidence already gathered, on the role that T cells play in SARS-CoV-2, how they might be used and what the Company’s specific plans are going forwards for its tests. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 8665756, approximately 15 minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately 60 days.About Oxford ImmunotecOxford Immunotec Global PLC is a global, high-growth diagnostics company. We bring energy and invention to a world in need of diagnostic truth. We are uniquely placed as the only company in the world offering regulated ELISPOT assays for T cell measurement, with approval around the globe. Our leading product, the T-SPOT®.TB test, is used for diagnosing infection with Tuberculosis, the world’s largest cause of death from infectious disease. The Company is an experienced manufacturer of IVD tests, operating under a fully audited Quality Management System, ensuring rigorous batch control. The company has manufactured in excess of 20 million clinical T cell tests for TB infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.CONTACTS:For Media and Investor Inquiries: Matt McLaughlin Chief Financial Officer Oxford Immunotec Tel: +1 (508) 573-9953 mtmclaughlin@oxfordimmunotec.com
GlobeNewswire · 11/23 12:30
Oxford Immunotec to Hold a Virtual Investor Event on December 17, 2020
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to hold a virtual investor event on Thursday, December 17, 2020. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will host a conference call from 10:00 a.m. to 12:00 p.m. Eastern Time. The call will be concurrently webcast with a slide presentation.
Globe Newswire · 11/23 12:30
Data Showing SARS-CoV-2 Reactive T Cells are Associated with Protection from COVID-19 and Can Be Both Detected and Measured Using Oxford Immunotecs T-SPOT® Technology is Published by Public Health England and Oxford Immunotec
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announced the release of data from a prospective cohort study in keyworkers in the UK – a collaboration between the Company and Public Health England (PHE). The data demonstrates that SARS-CoV-2 reactive T cells may be sufficient to give protection from COVID-19 and that serology alone may underestimate those at lower risk of clinical SARS-CoV-2 infection. The paper published on MedRxiv ‘SARS-CoV-2 responsive T cell numbers are associated with protection from COVID-19: A prospective cohort study in keyworkers’, presents data generated as part of the EDSAB-HOME study which investigated both antibody (serology) and T cell responses in a cohort of police, fire and healthcare workers.In the study, T cell tests were conducted at enrolment in almost 3,000 participants using the Company’s standardised research use only T-SPOT® Discovery SARS-CoV-2 assay. These individuals were then followed up for subsequent development of symptomatic, PCR confirmed SARS-CoV-2 infection. None of the participants with a high T cell response developed symptomatic SARS-CoV-2 infection in the follow-up period, whereas amongst those with low T cell responses there were 20 confirmed infections. Further follow-up is planned allowing for updated analyses as case numbers rise which may help yield additional insights into disease risk.These, and additional results from the data, suggest that: * Serology alone may underestimate the working age population at lower risk of clinical SARS-CoV-2 infection * Individual level risk stratification may be possible using T cell assays * Numbers of individuals with high levels of SARS-CoV-2 responsive T cells declines with increasing age, specifically in the absence of antibodies (serology), and this may explain higher illness incidence and severity in this group * The T-SPOT Discovery SARS-CoV-2 test detected PCR confirmed SARS-CoV-2 infections that were not positive in antibody (serology) testing.Dr. David Wyllie, Consultant Microbiologist at Public Health England and the lead author of the study, said, “We conducted a prospective cohort study in almost three thousand volunteers working in hospitals, and in the fire and police services in England. Four months into the study, 20 participants with lower T cell responses had developed COVID-19, compared with none among individuals with higher T cell responses. This suggests individuals with higher numbers of T-cells recognising SARS-CoV-2 may have some level of protection from COVID-19, although more research is required to confirm this.”Oxford Immunotec CEO, Dr Peter Wrighton-Smith said, “Our T-SPOT technology platform is the only globally regulated ELISPOT platform currently available and we are pleased that we may be able to use it to support efforts to combat COVID-19. Our collaboration with Public Health England is a great example of the public and private sector working together. The successful outcomes of this study would not have been possible without the specialist skills and resource available within Public Health England.”T-SPOT Discovery SARS-CoV-2 is for research use only, not for use in diagnostic proceduresNot all products are available in all regions, please contact us for information on availability in any specific countryFor further information visit: https://www.tspotdiscovery.com To view the publication visit: https://www.medrxiv.org/content/10.1101/2020.11.02.20222778v1About Oxford ImmunotecOxford Immunotec Global PLC is a global, high-growth diagnostics company. We bring energy and invention to a world in need of diagnostic truth. We are uniquely placed as the only company in the world offering regulated ELISPOT assays for T cell measurement, with approval around the globe. Our leading product, the T-SPOT®.TB test, is used for diagnosing infection with Tuberculosis, the world’s largest cause of death from infectious disease. The Company is an experienced manufacturer of IVD tests, operating under a fully audited Quality Management System, ensuring rigorous batch control. The company has manufactured in excess of 20 million clinical T cell tests for TB infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.About T-SPOT Discovery SARS-CoV-2Oxford Immunotec has been developing and strengthening its expertise in T cell measurement for over 15 years since the introduction of its T-SPOT technology in the field of TB diagnostics. In that time, we have taken the classic ELISPOT technique and developed it into the world leading proprietary T-SPOT technology platform we now use to measure T cell immune responses, improving performance, standardising results, and streamlining the workflow. This high performance is ensured by our regularly audited manufacturing facility operating to our rigorous quality management system. The T-SPOT.TB test, an in vitro diagnostic (IVD) test using the T-SPOT technology platform, has been granted regulatory approval for clinical diagnostic use in over 50 countries, including US, EU, Japan and China. The research use-only T-SPOT Discovery SARS-CoV-2 assay uses this same T-SPOT technology to allow SARS-CoV-2-specific T cells to be detected and enumerated. The optimized antigen mix used in the test is based on SARS-CoV-2 structural proteins and allows the maximum breadth of the immune response to be measured. The Company’s single antigen-per-well approach allows specific information about the immune response to different SARS-CoV-2 antigens to be gathered in parallel. Sample processing can be centralised whilst still enabling testing on fresh (rather than frozen) blood, using the Company’s T-Cell Xtend® reagent (32 hr room temperature (RT) sample stability) or T-Cell Select™ reagent (54 hr RT sample stability - automated processing). The T-Cell Select reagent kit also allows for automation and therefore accommodates variations in scale - automation solutions are available for low, medium and high throughput settings.About the EDSAB-HOME trialThe EDSAB-HOME trial is designed to address uncertainties around delivery of community-based mass antibody testing for previous SARS-CoV-2 infection, to allow rapid program development. The trial will evaluate the “first purchase” home test kits (HTKs) which the national program will be using, while providing a route to rapid validation & verification of alternatives which may be available later in 2020, including validation of industry enzyme immunoassay kits. The aim of the mass testing program will be to provide information to individuals as to whether they have been previously exposed to the virus. The first phase of the program has recruited over 3000 individuals from high risk (healthcare workers) and lower risk groups.T-SPOT, the Oxford Immunotec logo, T-Cell Xtend, T-Cell Select and T-SPOT Discovery are trademarks of Oxford Immunotec Limited.Forward-Looking StatementsCertain statements in this press release constitute forward-looking statements within the meaning of applicable U.S. and U.K. laws and regulations, including under the U.S. Private Securities Litigation Reform Act of 1995. Any statements contained herein which do not describe historical or current facts, including beliefs the Company’s research collaboration with PHE and the EDSAB-HOME trial and data results, including the success of the trial and beliefs about the data and related analyses; the belief that measuring T cells, in conjunction with other tests, may overcome limitations with the measurement of antibody-mediated immunity as well as other expected benefits of the T-SPOT Discovery SARS-CoV-2 test kit, including that the T cell assay may support efforts to combat COVID-19 and beliefs that the EDSAB-HOME trial will yield important information constitute forward-looking statements. Any forward-looking statements are based on our management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the possibility that the collaboration with PHE and the EDSAB-Home trial will not yield the expected benefits in a timely manner or at all, or that the results of the initial data analyses will not contribute to the study or assisting in COVID-19 efforts as expected; the Company’s Discovery line of testing might not be a successful or timely tool in combatting COVID-19, the risk that further research data from the Discovery test kit will not produce results that support its clinical use, the likelihood that the Company will be able to partner with a third party to make a testing device clinically available and the possibility that, even if ultimately made commercially available, the testing kit will not be efficacious in testing for or combatting COVID-19, as well as those other risks and uncertainties described in Oxford Immunotec’s filings with the U.S. Securities and Exchange Commission (the “Commission”), including the Company’s Annual Report on Form 10-K for the year-ended December 31, 2019 and its Quarterly Report on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020, and September 30, 2020 and in any other reports it files with the Commission, including any other Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Oxford Immunotec’s filings with the Commission are available for free by visiting the investor section of our website, www.oxfordimmunotec.com, or the Commission’s website, www.sec.gov.Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. Investors should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. Oxford Immunotec does not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.For Investor Inquiries: Matt McLaughlin Chief Financial Officer Oxford Immunotec Tel: +1 (508) 573-9953 mtmclaughlin@oxfordimmunotec.comFor Media Enquiries Peter Wrighton-Smith Chief Executive Officer Oxford Immunotec +44 1235 442796 info@oxfordimmunotec.com
GlobeNewswire · 11/10 14:00
Data Showing SARS-CoV-2 Reactive T Cells are Associated with Protection from COVID-19 - and Can Be Both Detected and Measured Using Oxford Immunotec's T-SPOT(R) Technology - is Published by Public Health England and Oxford Immunotec
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, today announced the release of data from a prospective cohort study in keyworkers in the UK - a collaboration between the Company and Public Health England (PHE). The data demonstrates that SARS-CoV-2 reactive T cells may be sufficient to give protection from COVID-19 and that serology alone may underestimate those at lower risk of clinical SARS-CoV-2 infection.
Globe Newswire · 11/10 14:00
Here's Why We're Not Too Worried About Oxford Immunotec Global's (NASDAQ:OXFD) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 11/05 16:44
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OXFD. Analyze the recent business situations of Oxford Immunotec through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OXFD stock price target is 18.25 with a high estimate of 21.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 122
Institutional Holdings: 29.10M
% Owned: 112.09%
Shares Outstanding: 25.96M
TypeInstitutionsShares
Increased
21
1.25M
New
17
435.76K
Decreased
24
1.17M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.17%
Healthcare Equipment & Supplies
+1.33%
Key Executives
Chairman/Independent Director
Patrick Balthrop
Chief Executive Officer/Director
Peter Wrighton-Smith
Chief Financial Officer
Matthew McLaughlin
General Counsel/Secretary
Janet Kidd
Independent Director
Ronald Andrews
Independent Director
Mark Klausner
Independent Director
Patricia Randall
Independent Director
Herman Rosenman
Independent Director
Richard Sandberg
Independent Director
James Tobin
Independent Director
Andrew Walton
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OXFD
Oxford Immunotec Global PLC,is a diagnostics company. It is focused on developing and commercializing tests for under-served immune-regulated conditions. Its product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Tick-borne disease is the collective name for diseases passed to humans through the bite of an infected tick. Its diagnostic tests for tick-borne infections include multiple laboratory developed tests (LDTs). Its tick-borne disease tests utilize molecular methods (such as polymerase chain reaction) and techniques to prosecute the immune system. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Oxford Immunotec Global PLC stock information, including NASDAQ:OXFD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OXFD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OXFD stock methods without spending real money on the virtual paper trading platform.